Limitations
SQUAMOUS CELL CARCINOMA, ADENOCARCINOMA
This study has some limitations. First, all patients in this study had squamous cell carcinoma, so the results may not be generalizable to adenocarcinoma. In addition, for financial reasons, PET CT is not part of the standard examination in China and was applied to patients only if it was available. Furthermore, due to poor adherence among included patients and the outbreak of the COVID-19 pandemic, 46 of 184 patients (25.0%) in the CRTCT group did not complete the entire course of chemotherapy, whereas only 9 patients (4.9%) in the CRTCT group died or relapsed before completing chemotherapy.